SecurityRVI / Retail Ventures Inc (76128Y102)
President & CEOLukes David R
Institutional Owners0
Common Shares Outstanding18,465,046 shares (as of 2018-06-30)
Related RVI.WI / Retail Value Inc.

Institutional Stock Ownership and Shareholders

Retail Ventures Inc (NYSE:RVI) has 0 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). Largest shareholders include .
Retail Ventures Inc (NYSE:RVI) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

File DateFormInvestor Opt Prev
Shares
Current
Shares
Change
(Percent)
Prev Value
($1000)
Current Value
($1000)
Change
(Percent)

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Related News Stories

EarthWater Announces New Product Promo and Launch Date of the New Super Affiliate Marketing Program Fulfilled By Amazon

2018-08-01 accesswire
DALLAS, TX / ACCESSWIRE / August 1, 2018 / EarthWater Ltd., a U.S. based health and wellness company manufacturer of high alkaline mineral infused beverages and health supplements announced two very exciting events today. First, an exclusive offer by EarthWater for new and existing Affiliates. Please go to www.earthwater.com/promo for immediate online shopping.

Retail Value Inc. Liquidation: A Hidden Gem?

2018-07-23 seekingalpha
RVI spun-out from DDR on July 2, 2018. RVI formed to hold 49 shopping center assets across the U.S. and Puerto Rico.

Retail Value's Initial Sales

2018-07-23 seekingalpha
Most initial sales have been for Florida assets. These may possibly be the easier assets to sell.

SA Interview: The Future Of Equity Research With Michael Boyd

2018-07-22 seekingalpha
The opportunities investors miss by relying on screens, when a non-actionable thesis can be just as valuable as an actionable one and the importance of being able to effectively communicate your thesis are topics discussed. (82-0)

Is DDR A Buy Post-RVI?

2018-07-17 seekingalpha
What would DDR's recent financial performance look like without the RVI assets that are now spun-off? (3-0)

CUSIP: 76128Y102